Article
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.
Blood cancer journal - 31 Mar 2017
Pawlyn C, Bright M D, Buros A F, Stein C K, Walters Z, Aronson L I, Mirabella F, Jones J R, Kaiser M F, Walker B A, Jackson G H, Clarke P A, Bergsagel P L, Workman P, Chesi M, Morgan G J, Davies F E
Abstract excerpt
Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for molecularly defined high-risk patients who continue to do badly. Novel therapeutic approaches are, therefore, required. A growing number of epigenetic inhibitors are now available including EZH2 inhibitors...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.